medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2012, Number 6

<< Back Next >>

Ann Hepatol 2012; 11 (6)

Steatotic livers. Can we use them in OLTX? Outcome data from a prospective baseline liver biopsy study

Gabrielli M, Moisan F, Vidal M, Duarte I, Jiménez M, Izquierdo G, Domínguez P, Méndez J, Soza A, Benitez C, Pérez R, Arrese M, Guerra J, Jarufe N, Martínez J

Language: English
References: 33
Page: 891-898
PDF size: 217.56 Kb.


ABSTRACT

Introduction. Steatotic livers have been associated with greater risk of allograft dysfunction in liver transplantation. Our aim was to determinate the prevalence of steatosis in grafts from deceased donors in Chile and to assess the utility of a protocol-bench biopsy as an outcome predictor of steatotic grafts in our transplant program. Material and methods. We prospectively performed protocol-bench graft biopsies from March 2004 to January 2009. Biopsies were analyzed and classified by two independent pathologists. Steatosis severity was graded as normal from absent to ‹ 6%; grade 1: 6-33%; grade 2: › 33-66% and grade 3:› 66%. Results. We analyzed 58 liver grafts from deceased donors. Twenty-nine grafts (50%) were steatotic; 9 of them (16%) with grade 3. Donor age (p ‹ 0.001) and BMI over 25 kg/m2 (p = 0.012) were significantly associated with the presence of steatosis. There were two primary non-functions (PNF); both in a grade 3 steatotic graft. The 3-year overall survival was lower among recipients with macrovesicular steatotic graft (57%) than recipients with microvesicular (85%) or non-steatotic grafts (95%) (p = 0.026). Conclusion. Macrovesicular steatosis was associated with a poor outcome in this series. A protocol bench-biopsy would be useful to identify these grafts.


REFERENCES

  1. Trevisani F, Colantoni A, Caraceni P, Van Thiel DH. The use of donor fatty liver for liver transplantation: a challenge or a quagmire? J Hepatol 1996; 24: 114-21.

  2. Adam R, Reynes M, Johann M, Morino M, Astarcioglu I, Kafetzis I, Castaing D, et al. The outcome of steatotic grafts in liver transplantation. Transplant Proc 1991; 23: 1538-40.

  3. Busuttil RW, Tanaka K. The utility of marginal donors in liver transplantation. Liver Transpl 2003; 9: 651-63.

  4. Bellentani S, Marino M. Epidemiology and natural history of non-alcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8(Suppl. 1): S4-S8.

  5. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez- Ayuso RM, González R, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int 2009; 29: 82-8.

  6. Hatta T, Fujinaga Y, Kadoya M, Ueda H, Murayama H, Kurozumi M, Ueda K, et al. Accurate and simple method for quantification of hepatic fat content using magnetic resonance imaging: a prospective study in biopsy-proven nonalcoholic fatty liver disease. J Gastroenterol 2010; 45: 1263-71.

  7. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-21.

  8. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.

  9. McCormack L, Petrowsky H, Jochum W, Mullhaupt B, Weber M, Clavien PA. Use of severely steatotic grafts in liver transplantation: a matched case-control study. Ann Surg 2007; 246: 940-6; Discussion 6-8.

  10. Durand F, Renz JF, Alkofer B, Burra P, Clavien PA, Porte RJ, Freeman RB, et al. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl 2008; 14: 1694-707.

  11. Petrowsky H, McCormack L, Trujillo M, Selzner M, Jochum W, Clavien PA. A prospective, randomized, controlled trial comparing intermittent portal triad clamping versus ischemic preconditioning with continuous clamping for major liver resection. Ann Surg. 2006; 244: 921-8; Discussion 8-30.

  12. Angele MK, Rentsch M, Hartl WH, Wittman B, Graeb C, Jauch KW, Loehe F. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am J Surg. 2008; 195: 214-20.

  13. Verran D, Kusyk T, Painter D, Fisher J, Koorey D. Strasser S, Stewart G, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003; 9: 500-5.

  14. El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, Puhan MA. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009; 250: 691-7.

  15. Imber CJ, St Peter SD, Lopez I, Guiver L, Friend PJ. Current practice regarding the use of fatty livers: a trans- Atlantic survey. Liver Transpl 2002; 8: 545-9.

  16. Trasplante Cd. Statistics. Santiago, 2011. Available from: http://www.trasplante.cl/estadisticas/index.php [Cited 2011 February, 07].

  17. Chen H, Peng CH, Shen BY, Deng XX, Shen C, Xie JJ, Dong W, et al. Multi-factor analysis of initial poor graft function after orthotopic liver transplantation. Hepatobiliary Pancreat Dis Int 2007; 6: 141-6.

  18. Briceno J, Ciria R, de la Mata M, Rufian S, Lopez-Cillero P. Prediction of graft dysfunction based on extended criteria donors in the model for end-stage liver disease score era. Transplantation 2010; 90: 530-9.

  19. Nickkholgh A, Weitz J, Encke J, Sauer P, Mehrabi A, Büchler MW, Schmidt J, et al. Utilization of extended donor criteria in liver transplantation: a comprehensive review of the literature. Nephrol Dial Transplant 2007; 22(Suppl. 8): viii29-viii36.

  20. Noujaim HM, de Ville de Goyet J, Montero EF, Ribeiro CM, Capellozi VL, Crescentini F, Casagrande M, et al. Expanding postmortem donor pool using steatotic liver grafts: a new look. Transplantation 2009; 87: 919-25.

  21. Halon A, Patrzalek D, Rabczynski J. Hepatic steatosis in liver transplant donors: rare phenomenon or common feature of donor population? Transplant Proc 2006; 38: 193-5.

  22. Loinaz C, Gonzalez EM. Marginal donors in liver transplantation. Hepatogastroenterology 2000; 47: 256-63.

  23. Spitzer AL, Lao OB, Dick AA, et al. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl 2010; 16: 874-84.

  24. McCormack L, Dutkowski P, El-Badry AM, Clavien PA. Liver transplantation using fatty livers: Always feasible? J Hepatol 2010.

  25. Selzner M, Clavien PA. Fatty liver in liver transplantation and surgery. Semin Liver Dis 2001; 21: 105-13.

  26. Nocito A, El-Badry AM, Clavien PA. When is steatosis too much for transplantation? J Hepatol 2006; 45: 494-9.

  27. Yoong KF, Gunson BK, Neil DA, Mirza DF, Mayer AD, Buckels JA, McMaster P. Impact of donor liver microvesicular steatosis on the outcome of liver retransplantation. Transplant Proc 1999; 31: 550-1.

  28. Fishbein TM, Fiel MI, Emre S, Cubucku O, Guy SR, Schwartz ME, Miller CM. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997; 64: 248-51.

  29. Urena MA, Ruiz-Delgado FC, Gonzalez EM, Segurola CL, Romero CJ, García IG, González-Pinto I, et al. Assessing risk of the use of livers with macro and microsteatosis in a liver transplant program. Transplant Proc 1998; 30: 3288-91.

  30. Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol 2007; 22: 778-87.

  31. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol 2007; 22: 788-93.

  32. Rey JW, Wirges U, Dienes HP, Fries JW. Hepatic steatosis in organ donors: disparity between surgery and histology? Transplant Proc 2009; 41: 2557-60.

  33. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, Boillot O, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of “seed and soil”. Am J Gastroenterol 2010; 105: 613-20.




2020     |     www.medigraphic.com